HepConnect
Gilead’s HepConnect initiative funds hepatitis C screening, harm reduction, and healthcare infrastructure projects in five Appalachian states impacted by the opioid crisis.
Funder: Gilead Sciences
Due Dates (Anticipated): June 2026 (annual application deadline, projected)
Funding Amounts: Funding levels not specified; details provided via initiative page or by inquiry.
Summary: Supports hepatitis C screening, harm reduction, and healthcare infrastructure projects in five Appalachian states affected by the opioid crisis.
Key Information: Eligibility and funding details may vary; check the initiative page for the latest requirements.
Description
HepConnect is a strategic initiative by Gilead Sciences designed to address the hepatitis C epidemic in five Appalachian states significantly impacted by the opioid crisis. The program aims to expand hepatitis C screening, support harm reduction services such as syringe programs and overdose prevention education, and strengthen healthcare infrastructure to better identify, treat, and support people living with or at risk for hepatitis C. The initiative partners with local organizations and health systems to drive sustainable improvements in public health and capacity building in affected communities.
